Summit Therapeutics, Inc.

November 20 is the #GreatAmericanSmokeout, a day that honors the strength it takes to begin a smoke free life. For many, it marks the first step toward better health, longer tomorrows, and greater self-empowerment. At #SummitTherapeutics, we believe that every effort to quit smoking is a step toward progress—not only for individuals, but for public health as a whole. When we support prevention, early intervention, and access to care, we are actively changing the future for the better, together. If you are thinking about quitting, today is a powerful time to start. Quit today. Breathe free tomorrow. Your journey matters. The @AmericanCancerSociety can help you access the resources and support you need to quit.  cancer.org/smokeout  #GASO #ACS #SMMTNewEra #TeamSummit #SummitTherapeutics  

In the United States, 1 in 18 people will be diagnosed with lung cancer in their lifetime. November is Lung Cancer Awareness Month, and this year, we want to educate the public about lung cancer. Know the facts, share the facts, and spread the word to raise much needed awareness. Learn more:  https://lnkd.in/gnDQazp5 Learn more: https://www.smmttx.com/  @lungevity #AnyoneWithLungs #LCAM #SMMTNewEra #SummitTherapeutics

November is #FamilyCaregiversMonth, a time to recognize the dedication, strength, and compassion of those who care for loved ones through illness, recovery, and everything in between. At #SummitTherapeutics, we recognize the vital role caregivers play in sustaining hope, supporting recovery, and bringing comfort during the most difficult moments. Your dedication reminds us that compassion is one of the most powerful tools in care. Join us in recognizing the strength of caregivers everywhere. Whether you are supporting a loved one or standing beside a patient, your presence makes a difference. Together, we are changing the future for the better. Learn more: https://www.smmttx.com/ #FamilyCaregiversMonth #SMMTNewEra #SummitTherapeutics

Summit Therapeutics is enrolling multiple Phase 3 clinical trials in Non-small Cell Lung Cancer (NSCLC). For more information please visit https://lnkd.in/exynuA3q or email medinfo@smmttx.com. #summittherapeutics, #SMMTNewEra, #nsclc, #oncologyclinicaltrials

November is #NationalCareerDevelopmentMonth, a time to recognize the power of growth, learning, and opportunity in shaping meaningful careers. At #SummitTherapeutics, growth is more than a goal – it is part of our mission. We are committed to investing in people just as much as in science. Through mentorship, innovation, and a culture of curiosity, we empower one another to pursue purpose-driven work that creates lasting impact.  Join us in celebrating the journeys that shape our teams and inspire progress. By growing together, we are changing the future for the better.  Learn more: https://www.smmttx.com/ #CareerDevelopmentMonth #SMMTNewEra #TeamSummit #SummitTherapeutics

Summit Therapeutics is enrolling multiple Phase 3 clinical trials in Non-small Cell Lung Cancer (NSCLC). For more information please visit https://lnkd.in/exynuA3q or email medinfo@smmttx.com. #summittherapeutics, #SMMTNewEra, #nsclc, #oncologyclinicaltrials

Summit Therapeutics is enrolling multiple Phase 3 clinical trials in Non-small Cell Lung Cancer (NSCLC). For more information please visit https://lnkd.in/exynuA3q or email medinfo@smmttx.com. #summittherapeutics, #SMMTNewEra, #nsclc, #oncologyclinicaltrials

November 8th is #LungCancerScreeningDay, a powerful reminder that early detection saves lives. Screening can help identify lung cancer in its earliest and most treatable stages, offering patients a better chance at recovery and more time with the people they love. At #SummitTherapeutics, we are committed to raising awareness about the importance of screening and early diagnosis. We believe that changing outcomes begins with informed action. It is through education and innovation that we are changing the future for the better, together. Help spread the word. Encourage someone you care about to talk to their doctor. Knowledge is power. Screening is strength. Your lungs and your life are worth it. Learn more: https://www.smmttx.com/  #LungCancerScreeningDay #ScreenToSave #SMMTNewEra  

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China The First Phase III Study Testing Ivonescimab Now Represents the First Statistically Significant OS Benefit Achieved by an Ivonescimab-Containing Regimen Ivonescimab Plus Chemotherapy Demonstrates Median OS of 16.8 Months vs. 14.1 Months, Respectively, for Patients Receiving Ivonescimab Plus Chemotherapy vs. Chemotherapy Alone; OS HR of 0.74 (p=0.019) Favorable Risk-Benefit Profile Observed in This Phase III Study Full Press Release Here: https://lnkd.in/g72yaVXR #SMMTNewERA #TeamSummit #Ivonescimab #OncologyResearch *Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).

We are honored to share that Dr. Allen Yang has been invited by the Society for Immunotherapy of Cancer (SITC) to present at SITC’s 40th Anniversary Annual Meeting, Nov. 7–9, 2025, at the Gaylord National Resort and Convention Center in National Harbor, MD. On Friday, Nov. 7, Dr. Yang will present on “Ivonescimab: A Novel First-in-Class PD-1 x VEGF Bispecific Antibody” as part of the session “The Next Wave: Viruses, Cells and Next-gen PD-1 Bispecifics.” This recognition is a testament to Dr. Yang’s expertise and dedication to advancing the field of cancer immunotherapy. #SummitTherapeutics is incredibly proud to see his work highlighted on such a prestigious stage. Learn more: https://www.smmttx.com/ *Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). #SITC2025 #SMMTNewEra #TeamSummit #Ivonescimab